These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 18079004)

  • 1. Failed efficacy of soluble human CD83-Ig in allogeneic mixed lymphocyte reactions and experimental autoimmune encephalomyelitis: implications for a lack of therapeutic potential.
    Pashine A; Göpfert U; Chen J; Hoffmann E; Dietrich PS; Peng SL
    Immunol Lett; 2008 Jan; 115(1):9-15. PubMed ID: 18079004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic activity of soluble CD83: comments on Pashine et al.
    Chou CP
    Immunol Lett; 2008 Jan; 115(1):20. PubMed ID: 18093663
    [No Abstract]   [Full Text] [Related]  

  • 3. Published studies reporting the efficacy of soluble CD83 in vitro as well as in vivo.
    Zinser E; Steinkasserer A
    Immunol Lett; 2008 Jan; 115(1):18-9. PubMed ID: 18054088
    [No Abstract]   [Full Text] [Related]  

  • 4. A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts.
    Xu JF; Huang BJ; Yin H; Xiong P; Feng W; Xu Y; Fang M; Zheng F; Wang CY; Gong FL
    Transpl Int; 2007 Mar; 20(3):266-76. PubMed ID: 17291220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD83: a regulatory molecule of the immune system with great potential for therapeutic application.
    Fujimoto Y; Tedder TF
    J Med Dent Sci; 2006 Jun; 53(2):85-91. PubMed ID: 16913569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83.
    Zinser E; Lechmann M; Golka A; Lutz MB; Steinkasserer A
    J Exp Med; 2004 Aug; 200(3):345-51. PubMed ID: 15289503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eukaryotic expression of functionally active recombinant soluble CD83 from HEK 293T cells.
    Staab C; Mühl-Zürbes P; Steinkasserer A; Kummer M
    Immunobiology; 2010; 215(9-10):849-54. PubMed ID: 20576314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD83: regulator of central T cell maturation and peripheral immune response.
    Breloer M
    Immunol Lett; 2008 Jan; 115(1):16-7. PubMed ID: 18022250
    [No Abstract]   [Full Text] [Related]  

  • 9. Engagement of CD83 on B cells modulates B cell function in vivo.
    Kretschmer B; Lüthje K; Schneider S; Fleischer B; Breloer M
    J Immunol; 2009 Mar; 182(5):2827-34. PubMed ID: 19234177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival.
    Bock F; Rössner S; Onderka J; Lechmann M; Pallotta MT; Fallarino F; Boon L; Nicolette C; DeBenedette MA; Tcherepanova IY; Grohmann U; Steinkasserer A; Cursiefen C; Zinser E
    J Immunol; 2013 Aug; 191(4):1965-75. PubMed ID: 23851696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy.
    Zhou H; Sequeira M; Goad ME; Erickson J; Wong A; Clark E; Dunussi-Joannopoulos K; Li RC; Friedrich S; Hayes LL; Wolf SF
    Clin Immunol; 2001 Dec; 101(3):303-14. PubMed ID: 11726223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of kidney allograft tolerance by soluble CD83 associated with prevalence of tolerogenic dendritic cells and indoleamine 2,3-dioxygenase.
    Lan Z; Ge W; Arp J; Jiang J; Liu W; Gordon D; Healey D; DeBenedette M; Nicolette C; Garcia B; Wang H
    Transplantation; 2010 Dec; 90(12):1286-93. PubMed ID: 21076370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2.
    Kumanogoh A; Marukawa S; Suzuki K; Takegahara N; Watanabe C; Ch'ng E; Ishida I; Fujimura H; Sakoda S; Yoshida K; Kikutani H
    Nature; 2002 Oct; 419(6907):629-33. PubMed ID: 12374982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local secretion/shedding of tumor-derived CD83 molecules as a novel tumor escape mechanism.
    Baleeiro RB; Barbuto JA
    Mol Immunol; 2008 Jul; 45(12):3502-4. PubMed ID: 18513799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell CD83: a therapeutic target or innocent bystander?
    Prazma CM; Tedder TF
    Immunol Lett; 2008 Jan; 115(1):1-8. PubMed ID: 18001846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance.
    Wang Q; Sun B; Wang D; Ji Y; Kong Q; Wang G; Wang J; Zhao W; Jin L; Li H
    Scand J Immunol; 2008 Dec; 68(6):607-15. PubMed ID: 18959624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous Expression of the Human CD83 Attenuates EAE Symptoms in Humanized Transgenic Mice and Increases the Activity of Regulatory T Cells.
    Zinser E; Naumann R; Wild AB; Michalski J; Deinzer A; Stich L; Kuhnt C; Steinkasserer A; Knippertz I
    Front Immunol; 2019; 10():1442. PubMed ID: 31293592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD83 regulates lymphocyte maturation, activation and homeostasis.
    Breloer M; Fleischer B
    Trends Immunol; 2008 Apr; 29(4):186-94. PubMed ID: 18329338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of chronic renal allograft rejection by soluble CD83.
    Lan Z; Lian D; Liu W; Arp J; Charlton B; Ge W; Brand S; Healey D; DeBenedette M; Nicolette C; Garcia B; Wang H
    Transplantation; 2010 Dec; 90(12):1278-85. PubMed ID: 21079552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies.
    Lechmann M; Kremmer E; Sticht H; Steinkasserer A
    Protein Expr Purif; 2002 Apr; 24(3):445-52. PubMed ID: 11922761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.